PODD Insulet Corporation
Company Analysis
Latest News
🟢 Insulet is trading 6.31% up in after-hours trading with limited support from broader market gains
Insulet is trading 6.31% up at $157.49 after closing at $148.14 on September 2, 2026, with limited support from broader market gains. - No September 2...
Insulet faces class-action deadline, following alleged Omnipod manufacturing defects
Robbins Geller Rudman & Dowd LLP and Faruqi & Faruqi, LLP reminded investors of an August 31, 2026, deadline to seek lead plaintiff status in a class-action...
🟢 Insulet is trading 11.08% up in after-hours trading; immediate trigger remains unclear
Insulet is trading 11.08% up at $164.43 after closing at $148.03 on August 18, 2026; the immediate after-hours trigger remains unclear. - Available August 18...
🟢 Insulet is trading 4.7% up today as healthcare gains 1.59%
Insulet is trading 4.7% up at $146.34, outperforming a broadly weaker market as healthcare gains 1.59% during the regular session. - No new positive...
🟢 Insulet is trading 15.13% up in after-hours trading
Insulet is trading 15.13% up at $167.01 after closing at $145.06 on August 12, 2026; no clear company-specific catalyst explaining the after-hours surge was...
🟢 Insulet is trading 9.51% up in after-hours trading
Insulet is trading 9.51% up at $158.85 in after-hours trading, but the catalyst remains unclear. - Shares closed at $145.06 on August 12, 2026. - No new...
Insulet Corporation faces securities class action lawsuit
Multiple law firms filed a class action lawsuit against Insulet Corporation. The suit alleges violations of federal securities laws. It claims Insulet made...
Insulet Beats on Every Q2 Metric Then Cuts the Outlook — Can the Type 2 Diabetes Bet Still Justify the Stock Price?
Shares of Insulet Corporation cratered 10.1% to $149.98 after the insulin-pump maker delivered a paradox: a strong quarter followed by a weaker road ahead....
🟢 Insulet is trading 4% up today as healthcare stocks gain
Insulet is trading 4% up at $138.59, with healthcare-sector strength providing the immediate backdrop. - It rebounded from the 20.12% decline on August 5. -...
🔴 Insulet is trading 23% down today as 2026 sales guidance cut offsets Q2 beat
Insulet is trading 23% down at $131.65 after its second-quarter earnings release showed strong revenue and EPS beats but a cut to full-year 2026 sales...
🔴 Insulet is trading 10.1% down today on lowered FY26 sales outlook and Omnipod guidance
Insulet is trading 10.1% down at $149.98 after the company lowered its long-term sales outlook despite beating Q2 earnings expectations. • The company cut its...
Insulet's second quarter revenue grew 23.5% to beat estimates, but the company lowered its full-year 2026 sales forecast.
Insulet reported second quarter revenue of $801.7 million, up 23.5% year-over-year, and adjusted EPS of $1.66. These results surpassed analyst expectations for...
Insulet Corporation Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Insulet to report Q2 2026 revenue of $787.4 million and earnings of $1.44 per share, with the stock currently trading at $165.35 against an...
🔴 Insulet is trading 4.6% down today as managed care concerns weigh on healthcare
Insulet is trading at $161.99 (4.6% down) as managed care concerns drag the broader healthcare sector lower despite positive performance in the wider...
Insulet Tumbles as UBS Slashes Omnipod Maker’s Price Target to $174
UBS downgraded Insulet Corp. (PODD) from Buy to Neutral on July 28, 2026. The investment bank slashed its price target for the medical device company to...
🟢 Insulet is trading 4.4% up today amid a broader healthcare sector bid
Insulet is trading at $172.25 (+4.40%) amid a broader healthcare sector bid and a rotation into defensive names, despite a lack of company-specific news. •...
🟢 Insulet is trading 4.2% up today despite broader healthcare sector weakness
Insulet is trading 4.2% higher at $166.13, moving notably above its recent $150–$160 range despite a lack of fresh company-specific catalysts. • No new...
🔴 Insulet shares fall 4.5% as class-action lawsuit filed today
• Insulet (PODD) is trading at $156.47 (-4.53%) today after a class-action lawsuit was filed against the company for securities fraud. • The lawsuit, announced...
Insulet's 6% Bounce Defies a Bruising Selloff — But Can Strong Sales Outrun a Growing Legal Cloud?
Shares of Insulet Corporation surged 6.1% to $174.55 on July 6, as bargain hunters stepped in following months of punishing declines. The stock has cratered...
🟢 PODD is trading 6.1% up today as investors reassess legal risks and fundamental strength
PODD is trading 6.1% up at $174.55 as investors reassess recent legal risks against the company's fundamental strength and upcoming earnings. • The move...